Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to differences in clinical, laboratory, and disease parameters. Although generally considered incurable, prognosis for early and advanced stage disease has improved because of therapeutic advances, several of which have resulted from elucidation of the biologic and molecular basis of the disease. The choice of treatment for FL is highly dependent on patient and disease characteristics. Several tools are available for risk stratification, although limitations in their routine clinical use exist. For limited disease, treatment options include radiotherapy, rituximab monotherapy or combination regimens, and surveillance. Treatment of advanced disease is often determined by tumor burden, with surveillance or rituximab considered for low tumor burden and chemoimmunotherapy for high tumor burden disease. Treatment for relapsed or refractory disease is influenced by initial first-line therapy and the duration and quality of the response. At present, there is no consensus for treatment of patients with early or multiply-relapsed disease; however, numerous agents, combination regimens, and transplant options have demonstrated efficacy. While the number of therapies available to treat FL has increased together with an improved understanding of the underlying biologic basis of disease, the best approach to select the most appropriate treatment strategy for an individual patient at a particular time continues to be elucidated. This chapter considers prognostic factors and the evolving treatment landscape of FL, including recent and emerging therapies, as well as remaining unmet needs.

滤泡 性淋巴瘤（FL）是一种异质性疾病，由于临床，实验室和疾病参数的差异，其预后也有所不同。尽管通常被认为是无法治愈的，但由于治疗的进展，早期和晚期疾病的预后有所改善，其中一些是由于阐明了疾病的生物学和分子基础而导致的。FL的治疗选择高度取决于患者和疾病特征。尽管存在常规临床使用的局限性，但仍有几种工具可用于风险分层。对于有限的疾病，治疗选择包括放疗，利妥昔单抗单药治疗或联合治疗以及监测。晚期疾病的治疗通常取决于肿瘤的负担，监测或利妥昔单抗用于低肿瘤负荷，而化学免疫疗法用于高肿瘤负荷疾病。复发或难治性疾病的治疗受到初始一线治疗以及反应持续时间和质量的影响。目前，对于早期或多发性疾病患者的治疗尚无共识。但是，许多药物，联合治疗方案和移植选择已证明具有疗效。尽管可用于治疗FL的疗法数量增加了，并且对疾病的潜在生物学基础有了更好的了解，但仍在阐明为特定患者在特定时间选择最合适的治疗策略的最佳方法。本章考虑了FL的预后因素和不断发展的治疗前景，